- Home
- MIRM vs OFG Comparison
MIRM vs OFG Comparison
Compare MIRM & OFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- OFG
- Stock Information
- Founded
- MIRM 2018
- OFG 1964
- Country
- MIRM United States
- OFG United States
- Employees
- MIRM N/A
- OFG N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- OFG Major Banks
- Sector
- MIRM Health Care
- OFG Finance
- Exchange
- MIRM Nasdaq
- OFG Nasdaq
- Market Cap
- MIRM 1.9B
- OFG 1.7B
- IPO Year
- MIRM 2019
- OFG N/A
- Fundamental
- Price
- MIRM $39.10
- OFG $35.81
- Analyst Decision
- MIRM Strong Buy
- OFG Buy
- Analyst Count
- MIRM 11
- OFG 3
- Target Price
- MIRM $58.55
- OFG $48.00
- AVG Volume (30 Days)
- MIRM 476.2K
- OFG 544.1K
- Earning Date
- MIRM 05-07-2025
- OFG 04-23-2025
- Dividend Yield
- MIRM N/A
- OFG 3.35%
- EPS Growth
- MIRM N/A
- OFG 10.44
- EPS
- MIRM N/A
- OFG 4.23
- Revenue
- MIRM $336,888,000.00
- OFG $629,438,000.00
- Revenue This Year
- MIRM $29.51
- OFG $5.54
- Revenue Next Year
- MIRM $20.27
- OFG $4.48
- P/E Ratio
- MIRM N/A
- OFG $8.47
- Revenue Growth
- MIRM 80.76
- OFG 0.13
- 52 Week Low
- MIRM $23.14
- OFG $33.15
- 52 Week High
- MIRM $54.23
- OFG $47.66
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- OFG 37.45
- Support Level
- MIRM $37.83
- OFG $35.04
- Resistance Level
- MIRM $40.32
- OFG $35.83
- Average True Range (ATR)
- MIRM 2.47
- OFG 1.56
- MACD
- MIRM -0.33
- OFG -0.10
- Stochastic Oscillator
- MIRM 25.14
- OFG 37.36
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About OFG OFG Bancorp
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.